Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 Perioperative Treatment for Rectal Cancer
NCT05300269Phase 2Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of retlirafusp alfa in rectal cancer, sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Treatment-Related Adverse Events at 16 weeks and Pathological Complete Response at 16 weeks. Started Jul 2022; status: recruiting.
02
Drugs
retlirafusp alfa
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05300269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05300269.